-
公开(公告)号:EP2714071B1
公开(公告)日:2019-07-10
申请号:EP12723117.3
申请日:2012-05-23
申请人: BioNTech RNA Pharmaceuticals GmbH , TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbH
-
公开(公告)号:EP3473267A1
公开(公告)日:2019-04-24
申请号:EP18199105.0
申请日:2012-05-23
申请人: BioNTech RNA Pharmaceuticals GmbH , TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbH
发明人: SAHIN, Ugur , KREITER, Sebastian , DIKEN, Mustafa , DIEKMANN, Jan , KOSLOWSKI, Michael , BRITTEN, Cedrik , CASTLE, John , LÖWER, Martin , RENARD, Bernhard , OMOKOKO, Tana , DE GRAAF, Johannes Hendrikus
摘要: The present invention relates to the provision of vaccines which are specific for a patient's tumor and are potentially useful for immunotherapy of the primary tumor as well as tumor metastases. In one aspect, the present invention relates to a method for providing an individualized cancer vaccine comprising the steps: (a) identifying cancer specific somatic mutations in a tumor specimen of a cancer patient to provide a cancer mutation signature of the patient; and (b) providing a vaccine featuring the cancer mutation signature obtained in step (a). In a further aspect, the present invention relates to vaccines which are obtainable by said method.
-
33.
公开(公告)号:EP3455625A1
公开(公告)日:2019-03-20
申请号:EP17726208.6
申请日:2017-05-10
申请人: BioNTech RNA Pharmaceuticals GmbH , TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbH
摘要: The present invention relates to methods for predicting peptides or polypeptides such as T cell epitopes useful for immunotherapy such as for vaccination. In particular, the present invention relates to methods for predicting whether peptides or polypeptides such as tumor-associated antigens or epitopes, in particular tumor-associated neoantigens or neoepitopes, are immunogenic and, in particular, useful for immunotherapy such as for vaccination. The methods of the invention may be used, in particular, for the provision of vaccines which are specific for a patient's tumor and, thus, in the context of personalized cancer vaccines.
-
公开(公告)号:EP2830593B1
公开(公告)日:2019-02-27
申请号:EP13713356.7
申请日:2013-03-25
申请人: BioNTech RNA Pharmaceuticals GmbH , TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbH
-
公开(公告)号:EP3417874A1
公开(公告)日:2018-12-26
申请号:EP18172228.1
申请日:2013-11-26
申请人: BioNTech RNA Pharmaceuticals GmbH , TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbH
IPC分类号: A61K39/00
CPC分类号: A61K39/0011 , A61K2039/53 , A61K2039/55561 , A61K2039/572 , A61K2039/605 , A61K2039/627
摘要: The present invention relates to a patient-specific tumor treatment targeting individual expression patterns of tumor antigens, in particular shared tumor antigens, and individual tumor mutations. In one aspect, the present invention relates to a method for preventing or treating cancer in a patient comprising the steps of: (i) inducing a first immune response against one or more tumor antigens in the patient, and (ii) inducing a second immune response against one or more tumor antigens in the patient wherein the second immune response is specific for cancer specific somatic mutations present in cancer cells of the patient.
-
公开(公告)号:EP3401334A1
公开(公告)日:2018-11-14
申请号:EP18168460.6
申请日:2008-05-27
申请人: Astellas Pharma Inc. , TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbH
发明人: SAHIN, Ugur , TÜRECI, Özlem , BRANDENBURG, Gunda , USENER, Dirk
IPC分类号: C07K16/30 , A61K39/395 , A61P35/00 , C12N5/12
CPC分类号: C07K16/28 , A61K2039/505 , C07K16/30 , C07K16/3046 , C07K2317/34 , C07K2317/73 , C07K2317/732 , C07K2317/734
摘要: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, cancer of the gallbladder, and the metastases thereof.
-
公开(公告)号:EP3049065A1
公开(公告)日:2016-08-03
申请号:EP13773604.7
申请日:2013-09-26
申请人: BioNTech AG , TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbH , Universitätsmedizin der Johannes Gutenberg-Universität Mainz
发明人: SAHIN, Ugur , HAAS, Heinrich , KREITER, Sebastian , HÜSEMANN, Yves , DIKEN, Mustafa , REUTER, Kerstin , HEFESHA, Hossam
IPC分类号: A61K9/127 , A61K48/00 , A61K9/50 , A61K31/663
CPC分类号: A61K39/39 , A61K9/1271 , A61K9/1277 , A61K9/5073 , A61K31/675 , A61K39/0011 , A61K2039/55505 , A61K2039/55511 , A61K2039/55516 , A61K2039/55555 , A61K2039/55561 , A61K2039/572 , C12N15/88 , C12N2810/10
摘要: The present invention relates to RNA decorated particles such as RNA decorated lipid particles, preferably to RNA decorated liposomes. Further, the present invention relates to a pharmaceutical composition comprising RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes. Said pharmaceutical composition is useful for inducing an immune response. It is also useful in a prophylactic and/or therapeutic treatment of a disease involving an antigen. Furthermore, the present invention relates to a method for producing the RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes.
-
公开(公告)号:EP3027203A1
公开(公告)日:2016-06-08
申请号:EP14747589.1
申请日:2014-07-30
申请人: BioNTech AG , TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbH
发明人: SAHIN, Ugur , PARET, Claudia , VORMBROCK, Kirsten , BENDER, Christian , SIMON, Petra , HARTMANN, Christoph , HUBICH, Stefanie , BUKUR, Thomas , LITZENBERGER, Thorsten
IPC分类号: A61K39/00 , A61K31/7105 , C07K14/47 , C12Q1/68 , G01N33/574
摘要: The present invention relates to the treatment of cancer, in particular breast cancer, particularly triple-negative breast cancer. More particularly, the invention concerns methods and means for cancer treatment involving a specific set of tumor antigens.
-
公开(公告)号:EP2920209A1
公开(公告)日:2015-09-23
申请号:EP13789492.9
申请日:2013-11-12
申请人: BioNTech AG , Ganymed Pharmaceuticals AG , TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbH
发明人: SAHIN, Ugur , TÜRECI, Özlem , STADLER, Christiane , HOLLAND, Julia , BÄHR-MAHMUD, Hayat , BEISSERT, Tim , PLUM, Laura , LE GALL, Fabrice , JENDRETZKI, Arne , FIEDLER, Markus
IPC分类号: C07K16/28
摘要: The present invention provides binding agents that contain a binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor- associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
-
公开(公告)号:EP2917350A1
公开(公告)日:2015-09-16
申请号:EP13792854.5
申请日:2013-11-07
申请人: BioNTech AG , TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbH , Universitätsmedizin der Johannes Gutenberg-Universität Mainz
发明人: SAHIN, Ugur , BEISSERT, Tim , POLEGANOV, Marco , HERZ, Stephanie , KOSTE, Lars
CPC分类号: C12N5/0696 , C12N2501/24 , C12N2501/602 , C12N2501/603 , C12N2501/604 , C12N2501/605 , C12N2501/606 , C12N2501/608 , C12N2501/65 , C12N2501/727 , C12N2506/1307 , C12N2510/00
摘要: The present invention relates to expressing RNA in cells and, in particular, enhancing viability of cells in which RNA is to be expressed. Specifically, the present invention provides methods for expressing RNA in cells comprising the steps of preventing engagement of IFN receptor by extracellular IFN and inhibiting intracellular IFN signalling in the cells. Thus, preventing engagement of IFN receptor by extracellular IFN and inhibiting intracellular IFN signalling in the cells allows repetitive transfer of RNA into the cells.
-
-
-
-
-
-
-
-
-